jeudi 31 août 2017

Onco Actu du 31 août 2017

2.6 Etiologie - Environnement

France to vote against license renewal for weedkiller glyphosate [Reuters]

3.1.1 Tabac - e-cigs

Most young people who try e-cigarettes don’t become regular users, says study [Cancer Research UK]

3.8 Prévention - Alimentation

The fat vs. carbs merry-go-round spins again [HealthNewsReview]

5. Traitements

Modified Stem Cells Deliver Chemotherapy to Metastatic Tumors [NCI]

5.12 Immunothérapies

Beta Blockers May Hold Key to Unleashing Potential of Checkpoint Inhibitors, Roswell Park Team Shows [Roswell Park Cancer Institute]

5.12.2 Immunothérapies - CAR-T

FDA approves Roche’s Actemra/RoActemra (tocilizumab) for the treatment of CAR T cell-induced cytokine release syndrome [Roche]

5.12.5 Immunothérapies - Pharma

Star team quietly raises $21M to launch the latest immuno-oncology startup Torque [EndPoints]

5.12.6 Immunothérapies - AMM

FDA Approves Pioneering Cancer Treatment With $475,000 Price Tag [Wall Street Journal]

ASH President Comments on FDA Approval of First CART-Cell Therapy to Treat Childhood Leukemia [ASH]

FDA Approves First CAR-T Cell Therapy for Pediatric Acute Lymphoblastic Leukemia [NIH Director's Blog]

A $475,000 price tag for a new cancer drug: crazy or meh? [STAT]

Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice [Novartis]

Novartis Wins Historic FDA Nod, Prices CAR-T For Leukemia at $475,000 [Xconomy]

Novartis crosses FDA finish line with monumental CAR-T leukemia approval [FiercePharma]

FDA Approves CAR T-cell Therapy for Pediatric Acute Lymphoblastic Leukemia [ACS]

FDA Approves Novartis Treatment That Alters Patients Cells To Fight Cancer [Forbes]

US approves first cancer drug to use patient's own cells – with $475,000 price tag [The Guardian]

Modified T cells that attack leukemia become first gene therapy approved in the United States [Science]

Novartis CEO's Dilemma: Is $475,000 Too Much For A Leukemia Breakthrough? Or Is It Not Enough? [Forbes]

FDA ushers in a new era in cancer treatment with ‘historic’ CAR-T approval for Novartis [EndPoints]

The FDA Has Approved the First ‘Gene Therapy’ for Cancer [MIT Technology Review]

F.D.A. Approves First Gene-Altering Leukemia Treatment, Costing $475,000 [NY Times]

FDA approval brings first gene therapy to the United States [FDA]

5.2.2 Pharma - Fusions & Acquisitions

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition [The Street]

5.6 ESMO

Bristol-Myers Squibb Data at ESMO 2017 Demonstrate Company’s Innovative Research Approach to Treating Cancer from All Angles [BMS]

Clovis Oncology to Present Comprehensive Dataset from Successful ARIAL3 Clinical Trial Program at 2017 ESMO Congress [Clovis]

5.6.4 ESMO - Poumon

ESMO 2017 Press Release: IFCT-0302 results question role of CT-scan in NSCLC post-surgery follow-up [ESMO]

AstraZeneca highlights latest advances in lung cancer at the ESMO 2017 Congress [AstraZeneca]

6.1 Observation

Publishing national chemotherapy data has helped NHS hospitals make changes that should improve treatment [Cancer Research UK]

6.7 DMP, Big Data & applis

UK needs to act urgently to secure NHS data for British public, report warns [The Guardian]

6.9 Controverses

In a Sign of Gene-Editing Frenzy, Startup Pitches Editing without CRISPR [MIT Technology Review]